Estimation of metformin and other sugar reducing therapy influence on the outcomes in patients with acute coronary syndrome and diabetes mellitus type II

Aim. To study the influence of hypoglycemic therapy on hospital and long-term prognosis in patients with acute coronary syndrome (ACS) and diabetes type 2.

Methods. The study included 63 patients with ACS and type 2 diabetes. All patients had a clinical examination, assessment of mortality risk and myocardial infarction on GRACE scale (Global Registry of Acute Coronary Events) and TIMI (Thrombolisis In Myocardial Infarction) in-hospital and six months after hospitalization.

Results. Metformin is associated with a lower estimated risk of in-hospital mortality and within 6 months after discharge in patients with acute coronary syndrome on the background of type 2 diabetes and with less risk of adverse cardiovascular events within 14 days of their occurrence in patients with unstable angina pectoris on the background of diabetes. High daily doses of metformin have also been associated with a decrease in the estimated risk of in-hospital mortality and within 6 months after discharge in patients with ACS associated with diabetes. The inverse association between the daily dosage of metformin and the presence of angina pectoris in patients with ACS and diabetes type 2 indicates a protective effect of metformin high daily dosages in relation to the risk of complications within six months after the discharge from hospital.

Conclusion. One of the important aspects of ACS treatment, along with effective therapy, is the impact on concomitant risk factors, including blood glucose control. The main groups of hypoglycemic drugs have currently been identified; their effect on cardiovascular events, long-term effects and long-term prognosis are being investigated.

1. Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. doi:10.15829/29/1560-4071-2020-4103 (In Russian)

2. Dedov I.I., Shestakova M.V., Mayorov A.Y., Vikulova O.K., Galstyan G.R., Kuraeva T.L. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. doi.org/10.14341/DM221S1 (In Russian)

3. Bondareva K.I., Nikolaev K.Yu. The influence of hypoglycemic therapy on the prognosis of acute coronary syndrome in patients with type 2 diabetes. Diabetes mellitus 2019: from monitoring to management. Materials of the III Russian multidisciplinary conference with international participation. 2019, С. 6-9. ISBN: 978-5-94520-042-5 (In Russian)

4. ESC guidelines for themanagement of acutemyocardial infarction in patients presenting with st-segment elevation 2017. Russ J Cardiol 2018; 23 (5): 103–158. doi.org/10.15829/1560-4071-2018-5-103-158 (In Russian)

5. GFR Calculator. National Kidney Foundation. Available at: https://www.kidney.org/professionals/kdoqi/gfr_calculator (accessed 05.02.2016).

6. Kal'kulyator shkaly Grace. Available at: http://www.rusintervention.ru/специалистам/медицинские–калькуляторы/шкала–grace/ (accessed 05.02.2016) (In Russian)

7. Bauters C., Lemesle G., de Groote P., Lamblin N. A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. Int J Cardiol. 2016;217:109-21. doi: 10.1016/j.ijcard.2016.04.182

8. Buckley L.F., Dixon D.L., Wohlford G.F. 4th, Wijesinghe D.S., Baker W.L., Van Tassell B.W. Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care 2017;40:1733-1738. Diabetes Care. 2018;41(6):e86-e87. doi: 10.2337/dci17-0066.

9. Ahmetov A.S. ADVANCE study – 20 years later. Endocrinology: News, Opinions, Training.2020; 9 (3): 11–2. doI:10.33029/2304-9529-2020-9-3-11-12 (In Russian)

10. Gerbaud E., Darier R., Montaudon M., Beauvieux M.C., Coffin-Boutreux C., Coste P., Douard H., Ouattara A., Catargi B. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome. Diabetes Care. 2019;42(4):674-681. doi: 10.2337/dc18-2047.

11. Jong C.B., Chen K.Y., Hsieh M.Y., Su F.Y., Wu C.C., Voon W.C., Hsieh I.C., Shyu K.G., Chong J.T., Lin W.S., Hsu C.N., Ueng K.C., Lai C.L. Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. Int J Cardiol. 2019;291:152-157. doi: 10.1016/j.ijcard.2019.03.021.

12. Bromage D.I., Godec T.R., Pujades-Rodriguez M., Gonzalez-Izquierdo A., Denaxas S., Hemingway H., Yellon D.M. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovasc Diabetol. 2019;18(1):168. doi: 10.1186/s12933-019-0972-4.

13. Mohsin A.A., Chen Q., Quan N., Rousselle T., Maceyka M.W., Samidurai A., Thompson J., Hu Y., Li J., Lesnefsky E.J. Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury. J Pharmacol Exp Ther. 2019;369(2):282-290. doi: 10.1124/jpet.118.254300.

14. Wang, Y., Yang, Z., Zheng, G., Yu L., Yin Y., Mu N., Ma H. Metformin promotes autophagy in ischemia/reperfusion myocardium via cytoplasmic AMPKα1 and nuclear AMPKα2 pathways. Life Sciences. 2019; 225: 64–71. doi:10.1016/j.lfs.2019.04.002

15. Varjabedian L., Bourji M., Pourafkari L. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs. 2018;18(3):181-193. doi:10.1007/s40256-018-0266-3.

16. Rena G., Hardie D.G., Pearson E.R. Pearson. The mechanisms of action of metformin. Diabetologia. 2017; 60(9): 1577–1585. doi:10.1007/s00125-017-4342-z.